Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Coronavirus update: U.S. death toll climbs above 150,000, and White House task force says 21 states are in the ‘red zone’
08:25pm, Wednesday, 29'th Jul 2020
The U.S. death toll from the coronavirus illness COVID-19 climbed above 150,000 on Wednesday, and the White House Task Force created to manage the pandemic...
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
08:05pm, Wednesday, 29'th Jul 2020
REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t
Roche's rheumatoid arthritis drug fails in COVID-19 trial
11:24am, Wednesday, 29'th Jul 2020
Shares of Roche Holding AG undefined were up 0.4% in premarket trading on Wednesday after the drugmaker said its rheumatoid arthritis drug Actemra failed in...
Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
04:44pm, Tuesday, 28'th Jul 2020
The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
03:52pm, Saturday, 25'th Jul 2020
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
08:23pm, Friday, 24'th Jul 2020
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Valeo Financial Advisors LLC Increases Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
08:05am, Wednesday, 22'nd Jul 2020
Valeo Financial Advisors LLC grew its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.2% in the second quarter, Holdings Channel.com reports. The institutional investor owned 447 shares o
Kistler Tiffany Companies LLC Increases Stock Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
07:30am, Wednesday, 22'nd Jul 2020
Kistler Tiffany Companies LLC boosted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 51.3% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 5
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
12:00pm, Tuesday, 21'st Jul 2020
REDWOOD CITY, Calif., July 21, 2020 -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare.
Raymond James Financial Services Advisors Inc. Has $10.40 Million Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
07:30am, Tuesday, 21'st Jul 2020
Raymond James Financial Services Advisors Inc. boosted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 89.8% in the second quarter, according to its most recent Form 13F filing with the Se
Did Hedge Funds Make The Right Call On Adverum Biotechnologies, Inc. (ADVM) ?
03:07pm, Monday, 20'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $619.00 at Morgan Stanley
08:42am, Sunday, 19'th Jul 2020
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by Morgan Stanley from $555.00 to $619.00 in a research note published on Wednesday morning, AnalystRatings.com reports. Morga
Wedbush Securities Inc. Grows Stock Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
08:08am, Sunday, 19'th Jul 2020
Wedbush Securities Inc. increased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 111.5% during the second quarter, according to the company in its most recent disclosure with the Secur
5 Biopharma Stocks That Are Affordable And Growing
10:30am, Friday, 17'th Jul 2020
Finding value among mature biopharma companies in the S&P 500 is increasingly tricky. Here are five for investors to consider.
